RCT: Mako Medial Unicondylar Knee Arthroplasty vs Oxford Unicondylar Knee Arthroplasty
Launched by UNIVERSITY COLLEGE, LONDON · Sep 17, 2019
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is comparing two different methods of knee surgery for patients with arthritis: the Mako robotic knee replacement and the traditional jig-based Oxford knee replacement. The goal is to see which method places the knee implant more accurately, which is important for better outcomes after surgery. Patients who are between 40 and 80 years old, have specific types of knee arthritis that require surgery, and can give informed consent may be eligible to participate.
If you decide to take part in the study, you'll have a chance to receive either the robotic or the traditional surgery. After the surgery, your progress will be monitored, and you'll undergo follow-up appointments to check how well the knee is healing. This research aims to help doctors understand which method might lead to better results for patients needing knee replacements in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • • Patient has medial unicompartmental knee osteoarthritis requiring primary UKA
- • Patient and Surgeon are in agreement that UKA is the most appropriate treatment
- • Patient is fit for surgical intervention following review by surgeon and anaesthetist
- • Patient is between 40-80 years of age at time of surgery
- • Gender: male and female
- • Patient must be capable of giving informed consent and agree to comply with the postoperative review program
- • Patient must be a permanent resident in an area accessible to the study site
- • Patient must have sufficient postoperative mobility to attend follow-up clinics and allow for radiographs to be taken
- Exclusion Criteria:
- • • Patient is not suitable for primary UKA e.g. multi-compartmental knee osteoarthritis, anterior cruciate ligament rupture
- • Patient is not medically fit for surgical intervention
- • Patient requires revision surgery following previously failed correctional osteotomy or ipsilateral UKA
- • Patient is immobile or has another neurological condition affecting musculoskeletal function
- • Patient is less than 40 years of age or greater than 80 years of age
- • Patient is already enrolled on another concurrent clinical trial
- • Patient is unable or unwilling to sign the informed consent form specific to this study
- • Patient is unable to attend the follow-up programme
- • Patient is non-resident in local area or expected to leave the catchment area postoperatively
About University College, London
University College London (UCL) is a leading global research institution renowned for its commitment to advancing healthcare through innovative clinical trials. As a prominent sponsor of clinical research, UCL leverages its multidisciplinary expertise and state-of-the-art facilities to conduct rigorous investigations aimed at improving patient outcomes and addressing pressing medical challenges. The institution fosters collaboration among researchers, healthcare professionals, and industry partners, ensuring that its trials adhere to the highest ethical standards and regulatory guidelines. UCL's dedication to translating scientific discoveries into practical applications underscores its role as a vital contributor to the advancement of medical science and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Patients applied
Trial Officials
Fares S Haddad
Study Chair
UCL Hospitals NHS Foundation Trust
Babar Kayani
Principal Investigator
UCL Hospitals NHS Foundation Trust
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials